2Dempfle CE, Argkiou S, Aiesci S, et al. Fibrin formation and proteolysis during ancrod treatment. Evidence for des-A-profibm formation and thrombh kadependent factor ⅩⅢ activity. Ann N YAcad Sci, 2001, 936:210 -214.
3Prentice CR, Hampton KK, G-rant PJ, et aL The fibrmolytic response to ancrod therapy: characterization of fibrinogen and fibrin degradation products. Br J Haematol, 1993, 83:276 -281.
4Izumi Y, Tsuda Y, Ichihara S, et al. Effects of defibrhaation on hemorhoology, cerebral blood flow velocity, and CO2 reactivity during hypoeapnia ha normal subjects. Stroke, 1996, 27:1328 - 1332.
5Rubsamen K, Homberger W, Kirchengast M. Inhibition of arterial thrombus formation m two canine models: comparison of ancrod, af ancrod a fibrinogen-depleting agent, the thrombin-inhibitor r-hirudin, and the glycoprotehl Ⅱb/Ⅲa-receptor antagonist Ro 43-8857. Thromb Haemost, 1995, 74:1353 - 1360.
6Hatton MW, Ross B, Southward SM, et al. Pretreatment of rabbits with either hitudin, ancrod, or warfarin significantly reduces the immediate uptake of iibrmogen and platelets by the deendothelialized aorta wall after balloon-catheter hjury in vivo. Artcriosclcr Thromb Vasc Biol, 1998, 18: 816 - 824.
7Elger B, Homberger W, Schwarz M, et al. MRI study on delayed ancrod therapy of focal cerebral ischaemia ha rats. Eur J Pharmacol, 1997, 336:7 - 14.
8Cercek B, Lew AS, Hod H, et al. Ancrod enhances the thrombolytic effect of streptokmase and urokmase. Thromb Res, 1987, 47:417 -426.
9Sherman DG, Atkinson RP, Chippendale T, et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled triaL Stroke Treatment with Ancrod Trial JAMA, 2000,283:2395 -2403.
